We are live on ! Find out more
FLGT icon

Fulgent Genetics

196 hedge funds and large institutions have $421M invested in Fulgent Genetics in 2023 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 51 increasing their positions, 74 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,719% more call options, than puts

Call options by funds: $67.6M | Put options by funds: $3.72M

11% more capital invested

Capital invested by funds: $380M → $421M (+$40.6M)

1.62% more ownership

Funds ownership: 47.54%49.16% (+1.6%)

10% less first-time investments, than exits

New positions opened: 28 | Existing positions closed: 31

2% less funds holding

Funds holding: 201196 (-5)

31% less repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 74

100% less funds holding in top 10

Funds holding in top 10: 20 (-2)

Holders
196
Holders Change
-5
Holders Change %
-2.49%
% of All Funds
2.86%
Holding in Top 10
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
New
28
Increased
51
Reduced
74
Closed
31
Calls
$67.6M
Puts
$3.72M
Net Calls
+$63.9M
Net Calls Change
+$48.6M
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$109M +$4.18M +156,307 +4%
Dimensional Fund Advisors
2
Dimensional Fund Advisors
Texas
$41.8M +$3.95M +147,505 +11%
Vanguard Group
3
Vanguard Group
Pennsylvania
$40.9M +$601K +22,480 +2%
State Street
4
State Street
Massachusetts
$23.5M +$1.09M +40,856 +5%
Morgan Stanley
5
Morgan Stanley
New York
$15.2M +$7.39M +276,215 +110%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$13.4M +$537K +20,070 +5%
PWAM
7
Park West Asset Management
California
$12.3M +$2.13M +79,649 +23%
Invesco
8
Invesco
Georgia
$10.7M +$1.52M +56,786 +18%
Millennium Management
9
Millennium Management
New York
$10.5M +$8.92M +333,299 +1,060%
JP Morgan Chase
10
JP Morgan Chase
New York
$9.7M +$1.22M +45,661 +16%
N
11
Nuveen
North Carolina
$7.97M +$255K +9,526 +4%
Charles Schwab
12
Charles Schwab
California
$7.73M +$887K +33,141 +14%
Ameriprise
13
Ameriprise
Minnesota
$7.25M +$4.93M +184,263 +278%
Northern Trust
14
Northern Trust
Illinois
$6.69M +$203K +7,588 +3%
Norges Bank
15
Norges Bank
Norway
$5.1M -$837K -31,300 -15%
Bank of New York Mellon
16
Bank of New York Mellon
New York
$4.51M -$1.55M -57,817 -27%
BCM
17
Bridgeway Capital Management
Texas
$4.44M -$1.1M -40,976 -21%
Point72 Asset Management
18
Point72 Asset Management
Connecticut
$4.37M +$3.98M +148,913 +6,205%
DSCM
19
Divisadero Street Capital Management
Florida
$3.97M -$19.3M -722,689 -84%
Jane Street
20
Jane Street
New York
$3.93M +$3.24M +121,060 +821%
Citadel Advisors
21
Citadel Advisors
Florida
$3.55M -$1.88M -70,136 -36%
TG
22
TCW Group
California
$3.37M
Principal Financial Group
23
Principal Financial Group
Iowa
$3.29M -$65K -2,431 -2%
Bank of America
24
Bank of America
North Carolina
$3M +$1.15M +42,910 +71%
Goldman Sachs
25
Goldman Sachs
New York
$2.96M -$34.5K -1,290 -1%

FLGT Hedge Fund Activity: Q4 2023 in Review

196 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Fulgent Genetics (FLGT) for Q4 2023, worth a combined $421M — up 11% from $380M a quarter earlier.

Sellers outnumbered buyers: 31 funds closed out of FLGT and 28 opened new positions — a net loss of 3 holders — while 74 trimmed existing stakes and 51 added.

The largest buyer was Millennium Management, adding an estimated $8.92M. The largest seller was Divisadero Street Capital Management, cutting an estimated $19.3M.

  • 196 institutional investors held Fulgent Genetics (FLGT) as of Q4 2023, down from 201 in Q3 2023.
  • Funds reported $421M of Fulgent Genetics stock for Q4 2023, up 11% quarter-over-quarter.
  • 28 funds opened new Fulgent Genetics positions in Q4 2023 and 31 closed out, a net change of -3 holders.
  • The largest Fulgent Genetics buyer in Q4 2023 was Millennium Management, an estimated $8.92M added.
  • The largest Fulgent Genetics seller in Q4 2023 was Divisadero Street Capital Management, an estimated $19.3M sold.

Based on aggregated 13F filings for Q4 2023.